Clovis Oncology, Inc. (CLVS): Price and Financial Metrics


Clovis Oncology, Inc. (CLVS): $4.43

-0.14 (-3.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

CLVS POWR Grades


  • CLVS scores best on the Growth dimension, with a Growth rank ahead of 75.49% of US stocks.
  • CLVS's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • CLVS ranks lowest in Sentiment; there it ranks in the 0th percentile.

CLVS Stock Summary

  • Clovis Oncology Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.42% of US listed stocks.
  • CLVS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.32% of US stocks.
  • Clovis Oncology Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -34.61%, greater than the shareholder yield of just 8.4% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Clovis Oncology Inc, a group of peers worth examining would be ARDX, BLDP, LOGC, SILC, and FBIO.
  • Visit CLVS's SEC page to see the company's official filings. To visit the company's web site, go to www.clovisoncology.com.

CLVS Valuation Summary

  • CLVS's price/sales ratio is 3.6; this is 68.28% lower than that of the median Healthcare stock.
  • Over the past 119 months, CLVS's price/sales ratio has gone NA NA.
  • CLVS's EV/EBIT ratio has moved up 1 over the prior 119 months.

Below are key valuation metrics over time for CLVS.

Stock Date P/S P/B P/E EV/EBIT
CLVS 2021-08-31 3.6 -2.8 -1.8 -3.6
CLVS 2021-08-30 3.6 -2.8 -1.8 -3.6
CLVS 2021-08-27 3.5 -2.7 -1.8 -3.6
CLVS 2021-08-26 3.4 -2.6 -1.7 -3.5
CLVS 2021-08-25 3.5 -2.6 -1.8 -3.5
CLVS 2021-08-24 3.5 -2.6 -1.7 -3.5

CLVS Growth Metrics

  • Its 3 year cash and equivalents growth rate is now at -44.05%.
  • Its 2 year revenue growth rate is now at 127.58%.
  • Its 2 year net income to common stockholders growth rate is now at -13.05%.
Over the past 33 months, CLVS's revenue has gone up $74,867,000.

The table below shows CLVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 156.944 -219.022 -310.359
2021-03-31 160.011 -232.124 -336.158
2020-12-31 164.522 -252.728 -369.212
2020-09-30 160.53 -266.822 -369.756
2020-06-30 159.361 -269.478 -385.155
2020-03-31 152.452 -307.658 -413.335

CLVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLVS has a Quality Grade of C, ranking ahead of 50.2% of graded US stocks.
  • CLVS's asset turnover comes in at 0.271 -- ranking 164th of 677 Pharmaceutical Products stocks.
  • FOLD, RDUS, and NSTG are the stocks whose asset turnover ratios are most correlated with CLVS.

The table below shows CLVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.271 0.746 -0.388
2021-03-31 0.269 0.746 -0.423
2020-12-31 0.271 0.749 -0.454
2020-09-30 0.258 0.753 -0.415
2020-06-30 0.244 0.754 -0.408
2020-03-31 0.228 0.761 -0.418

CLVS Price Target

For more insight on analysts targets of CLVS, see our CLVS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 2.17 (Hold)

CLVS Stock Price Chart Interactive Chart >

Price chart for CLVS

CLVS Price/Volume Stats

Current price $4.43 52-week high $11.10
Prev. close $4.57 52-week low $4.06
Day low $4.43 Volume 635,034
Day high $4.60 Avg. volume 7,915,495
50-day MA $4.75 Dividend yield N/A
200-day MA $5.74 Market Cap 524.56M

Clovis Oncology, Inc. (CLVS) Company Bio


Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The company was founded in 2009 and is based in Boulder, Colorado.


CLVS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLVS Latest Social Stream


Loading social stream, please wait...

View Full CLVS Social Stream

Latest CLVS News From Around the Web

Below are the latest news stories about Clovis Oncology Inc that investors may wish to consider to help them evaluate CLVS as an investment opportunity.

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

BOULDER, Colo., September 20, 2021--Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Yahoo | September 20, 2021

7 Penny Stocks Waiting on the FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.

Thomas Niel on InvestorPlace | September 9, 2021

Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

Why Clovis Oncology Shares Got a Bump This Week

Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.

The Motley Fool | August 27, 2021

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week

Short-squeeze stocks continue to be popular among retail traders as they look for targets to pump higher and we've got a list to watch.

William White on InvestorPlace | August 24, 2021

Read More 'CLVS' Stories Here

CLVS Price Returns

1-mo 4.48%
3-mo -28.20%
6-mo -32.98%
1-year -37.34%
3-year -86.32%
5-year -88.45%
YTD -7.71%
2020 -53.96%
2019 -41.95%
2018 -73.59%
2017 53.08%
2016 26.91%

Continue Researching CLVS

Here are a few links from around the web to help you further your research on Clovis Oncology Inc's stock as an investment opportunity:

Clovis Oncology Inc (CLVS) Stock Price | Nasdaq
Clovis Oncology Inc (CLVS) Stock Quote, History and News - Yahoo Finance
Clovis Oncology Inc (CLVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0954 seconds.